Adults skip the vaccines recommended for them. The barriers are mostly cost and access

Adults routinely miss the vaccines recommended for them, and the evidence suggests the main barriers are cost, insurance and the lack of a habitual adult-vaccine visit rather than outright refusal [s1][s2]. The clearest recent measure comes from pneumococcal vaccination: a pooled analysis of US survey data from 2019 to 2024 found overall coverage stuck between 29.6% and 33.2% across the years, far below the Healthy People 2020 goal of 90% [s1].

The shortfall is concentrated where the recommendation is newer or the population younger. Coverage reached 65.7% among adults 65 and older but only 23.0% among those aged 55–64, despite risk-based recommendations reaching into that group [s1]. Disparities by ethnicity were large: 13.9% of Hispanic adults reported pneumococcal vaccination against 29.1% of non-Hispanic White adults [s1]. These are not small gaps at the margins; they describe a system in which most eligible adults never get a vaccine their guidelines recommend [s1].

What predicts getting vaccinated

The determinants in that analysis point away from a simple story of vaccine hesitancy. Being 65 or older was strongly associated with vaccination (odds ratio 9.39), as were chronic conditions that mark higher risk — COPD (OR 2.04) and diabetes (OR 1.84) — consistent with vaccination happening when a person is already engaged with the health system for another reason [s1]. Conversely, lacking insurance (OR 0.89), having no usual source of care (OR 0.81), and not receiving the influenza vaccine (OR 0.29) all predicted lower odds of pneumococcal vaccination [s1]. That last association is telling: adults who skip one recommended vaccine tend to skip others, suggesting the issue is often whether an adult has any routine touchpoint where vaccines are offered at all [s1].

The natural experiment on cost

If cost is a real barrier, removing it should move coverage — and there is now evidence that it does. A US policy change eliminated out-of-pocket costs for recommended vaccines for Medicare Part D enrollees, creating a natural experiment for shingles vaccination, which had carried patient cost-sharing [s2]. An analysis estimated the policy increased shingles vaccinations by 26.3 per 10,000 Medicare Part D enrollees (95% confidence interval 11.2 to 41.4) relative to the trend [s2]. The effect is modest in absolute terms but points in the direction the access hypothesis predicts: lowering the price at the point of service raised uptake [s2].

What "catch-up" looks like

Unlike childhood immunisation, which is anchored to well-child visits and school requirements, adult vaccination has no comparable default structure — many adults simply never encounter a systematic offer [s3]. The CDC's adult schedule and its standards for adult immunisation practice are built around closing that gap: assessing vaccination status at clinical encounters, making a clear recommendation, and either administering or referring [s3]. The determinant data suggest those touchpoints matter more than persuasion, because the adults being missed are disproportionately those without insurance or a usual care provider — people who are hard to reach with any message [s1][s3].

The limits

Survey-based coverage relies on self-report and can misestimate true vaccination, and the determinants are associations that cannot prove, for any individual, why they were or were not vaccinated [s1]. The cost natural experiment isolates one barrier in one population and does not capture the full range of reasons adults go unvaccinated [s2]. But the consistent signal across the evidence — low coverage, steep social gradients, and responsiveness to cost and access — describes a delivery problem more than a demand problem [s1][s2]. This is an informational analysis of coverage data and guideline structure, not medical advice.